News | April 01, 2008

ACC/AHA Respond to Grassley's Letter on ENHANCE

April 1, 2008 - The American College of Cardiology (ACC) and American Heart Association (AHA) responded to Senate Finance Committee's senior Republican, Charles Grassley of Iowa, regarding his concerns about reports that two pharmaceutical companies delayed the release of the results from the ENHANCE trial.

The ENHANCE study, which was presented at the American College of Cardiology's 57th Annual Scientific Session on Sunday, March 30, 2008, and published online in the New England Journal of Medicine, compared the effect on carotid artery thickening of simvastatin alone versus simvastatin plus ezetimibe in patients with a genetic condition that causes severe increases in serum cholesterol. The results of the trial showed no benefit from the combination of ezetimibe (Zetia) and simvastatin (sold together as Vytorin) over simvastatin alone in terms of affecting the rate of atherosclerosis progression.

In a letter from Senator Grassley to the ACC, Grassley said that he was "troubled by reports that Merck and Schering Plough (M/SP) were delaying results of the ENHANCE trial," a study which examined whether Vytorin provides better health benefits than generic simvastatin-a drug that is far less expensive than Vytorin. The ENHANCE trial was completed in April 2006, but the results were not released for almost two years."

"Delaying the release of the results from the ENHANCE trial not only affected medical decisions, but also imposed financial burdens on patients as well as the federal government,"? he added.

Responding to Grassley's concerns, ACC CEO Jack Lewin, M.D., wrote a letter, in which the ACC/AHA Statement was enclosed, "We recognize the concerns regarding the delayed release of the data in the ENHANCE trial, and we were pleased to be able to provide a scientific venue to discuss the complete data from this study, and a forum to discuss the implications of the data on behalf of our members and their patients."

The ACC/AHA statement, which was issued on March 31, 2008, said, "While some of these data had been released previously, a complete peer-reviewed presentation had not been available." It added, "The study reinforces the need to adhere to current American College of Cardiology/American Heart Association Guidelines, which recommend statins to the maximally tolerated dose or to goal as first line treatment for patients with coronary artery disease. The data from the ENHANCE study should be considered as the NHLBI guidelines writing group is working on their update of the national cholesterol treatment guidelines in the coming months. Patients should speak with their physician before discontinuing any therapy."

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init